Catalyst Pharmaceuticals Inc
NASDAQ:CPRX

Watchlist Manager
Catalyst Pharmaceuticals Inc Logo
Catalyst Pharmaceuticals Inc
NASDAQ:CPRX
Watchlist
Price: 23.37 USD 0.39%
Market Cap: 2.9B USD
Section:
Relative Value
Valuation Multiples
Multiples Across Competitors
See Also

Relative Value

The Relative Value of one CPRX stock under the Base Case scenario is 24.51 USD. Compared to the current market price of 23.37 USD, Catalyst Pharmaceuticals Inc is Undervalued by 5%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

CPRX Relative Value
Base Case
24.51 USD
Undervaluation 5%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

5
P/S
P/S
Price to Sales
5
vs History
38
vs Industry
54
Median 3Y
4.9
Median 5Y
4.8
Industry
7.6
Forward
5
More Details
13.2
P/E
P/E
Price to Earnings
13.2
vs History
63
vs Industry
8
Median 3Y
18.2
Median 5Y
16.7
Industry
23.9
Forward
15.9
More Details
12.3
P/OCF
P/OCF
Price to OCF
12.3
vs History
33
vs Industry
12
Median 3Y
11.5
Median 5Y
11.5
Industry
20.8
More Details
12.3
P/FCFE
P/FCFE
Price to FCFE
12.3
vs History
33
vs Industry
11
Median 3Y
11.5
Median 5Y
11.6
Industry
22.4
More Details
3.1
P/B
P/B
Price to Book Value
3.1
vs History
69
vs Industry
23
Median 3Y
3.8
Median 5Y
3.6
Industry
3.1
More Details
3.8
EV/S
EV/S
Enterprise Value to Sales
3.8
vs History
52
vs Industry
49
Median 3Y
4.2
Median 5Y
3.8
Industry
8.2
Forward
3.8
More Details
4.4
EV/GP
EV/GP
Enterprise Value to Gross Profit
4.4
vs History
50
vs Industry
51
Median 3Y
4.9
Median 5Y
4.5
Industry
9.9
More Details
7.4
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
7.4
vs History
79
vs Industry
11
Median 3Y
11.2
Median 5Y
9.6
Industry
6.1
Forward
7.2
More Details
8.5
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
8.5
vs History
73
vs Industry
9
Median 3Y
12.9
Median 5Y
10.7
Industry
6.5
Forward
9.7
More Details
9.4
EV/OCF
EV/OCF
Enterprise Value to OCF
9.4
vs History
49
vs Industry
13
Median 3Y
9.6
Median 5Y
9.2
Industry
7.3
More Details
9.4
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
9.4
vs History
49
vs Industry
10
Median 3Y
9.6
Median 5Y
9.3
Industry
5.8
More Details
6.3
EV/IC
EV/IC
Enterprise Value to IC
6.3
vs History
58
vs Industry
22
Median 3Y
6.2
Median 5Y
6.3
Industry
5.3
More Details

Multiples Across Competitors

CPRX Competitors Multiples
Catalyst Pharmaceuticals Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
Catalyst Pharmaceuticals Inc
NASDAQ:CPRX
2.9B USD 5 13.2 7.4 8.5
FR
Pharnext SCA
OTC:PNEXF
6T USD 34 476 503.8 -163 861.7 -198 980.4 -196 709.8
US
Abbvie Inc
NYSE:ABBV
414.2B USD 6.9 176 17 24.1
US
Amgen Inc
NASDAQ:AMGN
180.4B USD 5 25.9 18.5 18.5
US
Gilead Sciences Inc
NASDAQ:GILD
158.2B USD 5.5 19.6 13.1 13.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
109B USD 9.3 29.6 21.7 22.6
US
Epizyme Inc
F:EPE
94.1B EUR 2 043.4 -521.4 -567.8 -552.6
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
81.1B USD 5.7 17.6 16.9 19.2
AU
CSL Ltd
ASX:CSL
88.6B AUD 3.7 19.1 12.8 16
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
57.2B USD 23.2 -179 -447.8 -307.4
NL
argenx SE
XBRU:ARGX
48.5B EUR 15.5 36.4 63.1 64.9
P/E Multiple
Earnings Growth PEG
US
Catalyst Pharmaceuticals Inc
NASDAQ:CPRX
Average P/E: 42.2
13.2
10%
1.3
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -163 861.7 N/A N/A
US
Abbvie Inc
NYSE:ABBV
176
89%
2
US
Amgen Inc
NASDAQ:AMGN
25.9
44%
0.6
US
Gilead Sciences Inc
NASDAQ:GILD
19.6
191%
0.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
29.6
N/A N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -521.4 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17.6
8%
2.2
AU
CSL Ltd
ASX:CSL
19.1
11%
1.7
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -179 N/A N/A
NL
argenx SE
XBRU:ARGX
36.4
37%
1
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
US
Catalyst Pharmaceuticals Inc
NASDAQ:CPRX
Average EV/EBITDA: 21.3
7.4
15%
0.5
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -198 980.4 N/A N/A
US
Abbvie Inc
NYSE:ABBV
17
14%
1.2
US
Amgen Inc
NASDAQ:AMGN
18.5
10%
1.8
US
Gilead Sciences Inc
NASDAQ:GILD
13.1
7%
1.9
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
21.7
16%
1.4
US
E
Epizyme Inc
F:EPE
Negative Multiple: -567.8 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
16.9
9%
1.9
AU
CSL Ltd
ASX:CSL
12.8
8%
1.6
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -447.8 N/A N/A
NL
argenx SE
XBRU:ARGX
63.1
769%
0.1
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
US
Catalyst Pharmaceuticals Inc
NASDAQ:CPRX
Average EV/EBIT: 23.4
8.5
18%
0.5
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -196 709.8 N/A N/A
US
Abbvie Inc
NYSE:ABBV
24.1
30%
0.8
US
Amgen Inc
NASDAQ:AMGN
18.5
19%
1
US
Gilead Sciences Inc
NASDAQ:GILD
13.1
13%
1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
22.6
17%
1.3
US
E
Epizyme Inc
F:EPE
Negative Multiple: -552.6 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
19.2
12%
1.6
AU
CSL Ltd
ASX:CSL
16
11%
1.5
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -307.4 N/A N/A
NL
argenx SE
XBRU:ARGX
64.9
N/A N/A

See Also

Summary
CPRX intrinsic value, competitors valuation, and company profile.
DCF Valuation
CPRX stock valuation using Discount Cash Flow valuation method.
Relative Valuation
CPRX stock valuation using valuation multiples.
Wall Street Estimates
CPRX price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
CPRX stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 298,600+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.